We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-30.82%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$2.7B
AUM Growth
-$1.14B
Cap. Flow
+$156M
Cap. Flow %
5.8%
Top 10 Hldgs %
59.73%
Holding
123
New
18
Increased
25
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
MRNA icon
Moderna
MRNA
+$86.4M
2
BABA icon
Alibaba
BABA
+$51.3M
3
NIO icon
NIO
NIO
+$28.5M
4
ALLO icon
Allogene Therapeutics
ALLO
+$10.6M
5
ARRY
Array Biopharma Inc
ARRY
+$9.1M

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$31.2M
2
ANAB icon
AnaptysBio
ANAB
+$11.2M
3
FOLD
Amicus Therapeutics
FOLD
+$11M
4
ZGNX
Zogenix, Inc.
ZGNX
+$8.19M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$7.69M

Sector Composition

Rank Sector Weight
1 Healthcare 49.34%
2 Miscellaneous 25.7%
3 Consumer Discretionary 24.57%
4 Real Estate 0.28%
5 Communication Services 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WW
1
DELISTED
WW International
WW
$571M 21.16%
14,818,300
– –
LXRX icon
2
Lexicon Pharmaceuticals
LXRX
$890M
$400M 14.82%
60,240,864
– –
GM icon
3
CALL
General Motors
GM
$75.1B
$117M 4.34%
3,500,000
+500,000
+17% +$17.3M
BAC icon
4
CALL
Bank of America
BAC
$416B
$111M 4.11%
4,500,000
– –
ONC
5
BeOne Medicines Ltd
ONC
$39.2B
$84.2M 3.12%
600,000
– –
MRNA icon
6
Moderna
MRNA
$58.6B
$80.3M 2.97%
+5,256,298
New +$86.4M
WFC icon
7
CALL
Wells Fargo
WFC
$273B
$69.1M 2.56%
1,500,000
– –
CELG
8
CALL
DELISTED
Celgene Corp
CELG
$64.1M 2.37%
1,000,000
+250,000
+33% +$18.5M
MS icon
9
CALL
Morgan Stanley
MS
$337B
$59.5M 2.2%
1,500,000
-500,000
-25% -$21.8M
BABA icon
10
Alibaba
BABA
$272B
$56.5M 2.09%
412,000
+347,000
+534% +$51.3M
SRRK icon
11
Scholar Rock
SRRK
$6.75B
$52.7M 1.95%
2,296,040
-100,000
-4% -$2.26M
RUBY
12
DELISTED
Rubius Therapeutics, Inc
RUBY
$46.8M 1.73%
2,908,791
– –
XLRN
13
DELISTED
Acceleron Pharma
XLRN
$45.7M 1.69%
1,050,000
+50,000
+5% +$2.5M
GS icon
14
CALL
Goldman Sachs
GS
$288B
$41.8M 1.55%
250,000
-800,000
-76% -$161M
ALNY icon
15
Alnylam Pharmaceuticals
ALNY
$33.5B
$36.5M 1.35%
500,000
-100,000
-17% -$7.69M
NIO icon
16
NIO
NIO
$9.2B
$35.7M 1.32%
5,600,000
+4,100,000
+273% +$28.5M
ARRY
17
DELISTED
Array Biopharma Inc
ARRY
$35.6M 1.32%
2,500,000
+600,000
+32% +$9.1M
ATRA icon
18
Atara Biotherapeutics
ATRA
$94.2M
$34.7M 1.29%
40,000
– –
BPMC
19
DELISTED
Blueprint Medicines
BPMC
$32.3M 1.2%
600,000
+100,000
+20% +$6.08M
FOLD
20
DELISTED
Amicus Therapeutics
FOLD
$28.7M 1.06%
3,000,000
-1,000,000
-25% -$11M
BMY icon
21
CALL
Bristol-Myers Squibb
BMY
$130B
$28.6M 1.06%
550,000
-200,000
-27% -$10.7M
ONC
22
CALL
BeOne Medicines Ltd
ONC
$39.2B
$28.1M 1.04%
+200,000
New +$26.5M
FATE icon
23
Fate Therapeutics
FATE
$277M
$27.6M 1.02%
2,150,000
-40,000
-2% -$558K
NKTR icon
24
Nektar Therapeutics
NKTR
$2.34B
$26.3M 0.97%
53,333
– –
ARGX icon
25
argenx
ARGX
$61.6B
$25.9M 0.96%
270,000
+85,000
+46% +$7.55M
1
2 3 4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2018 Portfolio in Review

As of Q4 2018, Artal Group held 123 positions worth $2.7B, down 30% from $3.84B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Artal Group deployed $156M of net new capital in Q4 2018, opening 18 new positions and adding to 25 existing holdings. Its largest new stake was Moderna: 5,256,298 shares worth $80.3M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, up from 46% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

On the sell side, the largest reduction was AnaptysBio, an estimated $11.2M trimmed.

  • Artal Group's largest Q4 2018 buy was Moderna: 5,256,298 shares worth $80.3M.
  • Artal Group added most to Alibaba in Q4 2018, an estimated $51.3M increase.
  • Artal Group's biggest Q4 2018 reduction was AnaptysBio, cutting an estimated $11.2M.
  • Artal Group fully exited TESARO, Inc. in Q4 2018, selling an estimated $31.2M.
  • Artal Group's ten largest holdings make up 60% of its $2.7B portfolio in Q4 2018.
  • Artal Group opened 18 new positions and closed 19 in Q4 2018.
  • Artal Group's portfolio value fell 30% quarter-over-quarter to $2.7B.

Based on Artal Group's 13F filing for Q4 2018, filed 11 Feb 2019.